![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: GLB1L3 |
Gene summary for GLB1L3 |
![]() |
Gene information | Species | Human | Gene symbol | GLB1L3 | Gene ID | 112937 |
Gene name | galactosidase beta 1 like 3 | |
Gene Alias | GLB1L3 | |
Cytomap | 11q25 | |
Gene Type | protein-coding | GO ID | GO:0005975 | UniProtAcc | Q8NCI6 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
112937 | GLB1L3 | RNA-P6T2-P6T2-1 | Human | Lung | IAC | 2.31e-18 | 5.45e-01 | -0.0166 |
112937 | GLB1L3 | RNA-P6T2-P6T2-2 | Human | Lung | IAC | 2.12e-26 | 6.94e-01 | -0.0132 |
112937 | GLB1L3 | RNA-P6T2-P6T2-3 | Human | Lung | IAC | 5.10e-22 | 6.35e-01 | -0.013 |
112937 | GLB1L3 | RNA-P6T2-P6T2-4 | Human | Lung | IAC | 8.40e-12 | 4.36e-01 | -0.0121 |
112937 | GLB1L3 | RNA-P7T1-P7T1-1 | Human | Lung | AIS | 2.37e-02 | 3.64e-01 | -0.0961 |
112937 | GLB1L3 | RNA-P7T1-P7T1-3 | Human | Lung | AIS | 2.91e-02 | 3.23e-01 | -0.0822 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Lung | ![]() | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ | ||
IAC: Invasive lung adenocarcinoma | ||
MIA: Minimally invasive adenocarcinoma |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
GLB1L3 | SNV | Missense_Mutation | novel | c.1940N>A | p.Ser647Tyr | p.S647Y | Q8NCI6 | protein_coding | deleterious(0.02) | benign(0.04) | TCGA-EO-A3AV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | CR |
GLB1L3 | SNV | Missense_Mutation | rs201605779 | c.1673N>A | p.Arg558His | p.R558H | Q8NCI6 | protein_coding | tolerated(0.58) | benign(0.125) | TCGA-EO-A3AY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
GLB1L3 | SNV | Missense_Mutation | novel | c.715N>T | p.Pro239Ser | p.P239S | Q8NCI6 | protein_coding | tolerated(0.24) | benign(0.021) | TCGA-EO-A3B0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
GLB1L3 | SNV | Missense_Mutation | c.662C>T | p.Ala221Val | p.A221V | Q8NCI6 | protein_coding | deleterious(0) | possibly_damaging(0.898) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD | |
GLB1L3 | SNV | Missense_Mutation | novel | c.752T>C | p.Val251Ala | p.V251A | Q8NCI6 | protein_coding | tolerated(0.72) | benign(0.021) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
GLB1L3 | SNV | Missense_Mutation | novel | c.884A>C | p.Lys295Thr | p.K295T | Q8NCI6 | protein_coding | tolerated(0.05) | possibly_damaging(0.463) | TCGA-QS-A5YQ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
GLB1L3 | deletion | Frame_Shift_Del | rs758614894 | c.1233delC | p.Val412Ter | p.V412* | Q8NCI6 | protein_coding | TCGA-D1-A2G5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | ||
GLB1L3 | SNV | Missense_Mutation | c.714G>A | p.Met238Ile | p.M238I | Q8NCI6 | protein_coding | deleterious(0) | possibly_damaging(0.665) | TCGA-DD-A3A7-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | III/IV | Chemotherapy | unknown | PD | |
GLB1L3 | SNV | Missense_Mutation | novel | c.1012G>A | p.Val338Ile | p.V338I | Q8NCI6 | protein_coding | tolerated(0.12) | benign(0.007) | TCGA-DD-AA3A-01 | Liver | liver hepatocellular carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
GLB1L3 | SNV | Missense_Mutation | novel | c.1844C>A | p.Pro615His | p.P615H | Q8NCI6 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-RC-A6M4-01 | Liver | liver hepatocellular carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |